Thus the strategic enhanced production of transgene IL-15 by IL-15Rα+ DC likely plays a major role in the superior ability of DCIL-15-based cancer vaccines to promote robust antitumor CD8+ T cell responses including those from central memory CD8+ T cells (CD8+CD44hiCD62Lhi) and effector memory CD8+ T cells (CD8+CD44hiCD62Llo) in tdLN (Fig. S3). This evidence concerns the gene CD8A and cancer.